Advertisement
New Zealand markets closed

  • NZX 50

    11,755.17
    +8.59 (+0.07%)
     

  • NZD/USD

    0.6013
    -0.0021 (-0.35%)
     

  • NZD/EUR

    0.5584
    -0.0010 (-0.17%)
     

  • ALL ORDS

    8,022.70
    +28.50 (+0.36%)
     

  • ASX 200

    7,749.00
    +27.40 (+0.35%)
     

  • OIL

    79.35
    +0.09 (+0.11%)
     

  • GOLD

    2,372.20
    +31.90 (+1.36%)
     

  • NASDAQ

    18,126.18
    +12.71 (+0.07%)
     

  • FTSE

    8,437.49
    +56.14 (+0.67%)
     

  • Dow Jones

    39,512.35
    +124.59 (+0.32%)
     

  • DAX

    18,772.53
    +85.93 (+0.46%)
     

  • Hang Seng

    18,963.68
    +425.87 (+2.30%)
     

  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

  • NZD/JPY

    93.6730
    -0.0950 (-0.10%)
     

Analyzing Baxter International’s Operational Performance

Kenneth Smith
Updated
Analyzing Baxter International’s Operational Performance

Sales from Baxter International’s (BAX) advanced surgery business, which includes biological products and medical devices that are used in surgical procedures, increased from $178 million in the second quarter of 2017 to $204 million in the second quarter of 2018. The marketing and administrative expenses incurred by Baxter International increased from $630 million in the second quarter of 2017 to $681 million in the second quarter of 2018.

Continue reading